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ABSTRACT: Improvements in cardiovascular disease (CVD) rates among young adults in the past 2 decades have been offset
by increasing racial/ethnic and gender disparities, persistence of unhealthy lifestyle habits, overweight and obesity, and other
CVD risk factors. To enhance the promotion of cardiovascular health among young adults 18 to 39 years old, the medical
and broader public health community must understand the biological, interpersonal, and behavioral features of this life stage.
Therefore, the National Heart, Lung, and Blood Institute, with support from the Office of Behavioral and Social Science
Research, convened a 2-day workshop in Bethesda, Maryland, in September 2017 to identify research challenges and opportunities related to the cardiovascular health of young adults. The current generation of young adults live in an environment
undergoing substantial economic, social, and technological transformations, differentiating them from prior research cohorts
of young adults. Although the accumulation of clinical and behavioral risk factors for CVD begins early in life, and research
suggests early risk is an important determinant of future events, few trials have studied prevention and treatment of CVD in
participants <40 years old. Building an evidence base for CVD prevention in this population will require the engagement of
young adults, who are often disconnected from the healthcare system and may not prioritize long-term health. These changes
demand a repositioning of existing evidence-based treatments to accommodate new sociotechnical contexts. In this article,
the authors review the recent literature and current research opportunities to advance the cardiovascular health of today’s
young adults.
Key Words: cardiovascular disease prevention ■ cardiovascular disease risk factors ■ primary prevention ■ young adults

D

espite an overall population-wide decline in cardiovascular disease (CVD) mortality in the United
States since 1968,1 detailed analysis of age-specific rates reveals concerning trends within young adult
populations. For example, the proportion of acute
myocardial infarctions attributable to patients <55

years old has increased from 27% to 32% in the past
20 years.2 and among women 35 to 44 years old, the
mortality rate from CVD has increased ≈1.3% per year
(95% CI, 0.2–2.5) since 1997.3 Acute ischemic stroke
hospitalizations have also increased significantly for
men and women 18 to 44 years old, with men 35 to
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44 years old demonstrating a doubling of acute ischemic stroke hospitalizations since 1996.4 Although improvements have been made in acute cardiovascular
care, these gains have been offset by increasing racial/
ethnic and gender disparities, persistence of unhealthy
lifestyle habits, overweight and obesity, and other
CVD risk factors such as diabetes mellitus (DM) and
hypertension.2,4–7
To enhance efforts promoting the cardiovascular
health (CVH) of young adults, defined as 18 to 39 years
old, the medical and broader public health community
should understand the unique confluence of biological,
interpersonal, and behavioral features of this life stage.
The current generation of 21st century young adults
live in an environment undergoing substantial economic, social, and technological transformations, differentiating them from young adults just 10 or 20 years
ago. These changes demand a refashioning of existing
evidence-based treatments to accommodate new sociotechnical contexts. Building an evidence base for
CVD prevention in this population will require engagement of young adults, who are often disconnected
from the healthcare system and may be unmotivated
or unable to prioritize their long-term health. Although
the accumulation of clinical and behavioral risk factors
for CVD begins early in the life course, few trials have
studied prevention and treatment of CVD in participants <40 years old.
The National Heart, Lung, and Blood Institute
(NHLBI), with support from the Office of Behavioral
and Social Science Research, convened a 2-day
workshop in Bethesda, Maryland, in September
2017 to identify research challenges and opportunities related to the CVH of young adults. Further details of the meeting and deliberations of the working
group can be found on the NHLBI website.8 A smaller
writing group comprised of 5 members of the working group later convened to develop 2 conceptual
frameworks summarizing the presentations of the
independent experts. The first framework (Figure 1),
inspired by the socioecological model9 and the

pathways linking socioeconomic status (SES) and
health model,10 conceptualizes the CVH of young
adults as influenced by individual, demographic, and
community factors situated within a contemporary
context. The second framework (Figure 2), inspired
by the Life Course Health Development Framework,11
posits how these various influences create enduring
vulnerabilities that influence the trajectory of CVH
during and after young adulthood. The writing group
then worked with NHLBI staff and each member of
the working group to update the recent literature in
their respective domains. Consistent with the original
goals of the workshop and funding priorities of the
NHLBI, in this article we focus primarily on atherosclerotic coronary heart disease (CHD) and its risk
factors, although related health conditions such as
DM and stroke are discussed where relevant. We review the recent literature and conclude with suggestions for research to address the unique CVH needs
of today’s young adults.

CVH OF YOUNG ADULTS
Young adulthood encompasses the age range between 18 and 39 years old.12 During this period, young
adults may complete their education, enter the workforce, establish social networks and romantic relationships, create a family, and set financial goals.13 Critical
health behaviors are either established or lost, helping to shape a life-long trajectory of CVH and wellbeing.14,15 Importantly, young adults often become
parents, thereby initiating intergenerational CVH patterns and exposures.
In 2010, the American Heart Association set the
bold goal of improving CVH of all Americans by 20%
by 2020.16 To assess CVH, it chose 4 lifestyle factors
(nonsmoking status, healthy diet, physical activity patterns, and healthy weight) and 3 clinical factors (optimal
blood pressure, blood glucose, and blood lipid levels)
consistently shown in epidemiologic studies to be associated with living longer, healthier lives. For the 7 metrics
(with the exception of diet) and for the CVH construct
overall, children and adolescents are much more likely
to have ideal levels than adults. The “Heart Disease and
Stroke Statistics—2020 Update” from the American
Heart Association addresses these trends (see Figure 3
excerpted from the update) based on data from the
National Health and Nutrition Examination Survey.17
The transition from the relatively ideal CVH of
children to the poor CVH of older adults occurs in
young adulthood. Considerably fewer young adults
(35.2%) meet the criteria for ideal body mass index
(BMI) compared with adolescents (60.1%). Young
adults are also less likely than adolescents to meet
ideal levels of total cholesterol, blood pressure, and
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Figure 1. Multilevel influences on young adult cardiovascular health.
The multilevel factors influencing young adult cardiovascular health are depicted here as concentric circles including individual,
interpersonal, and community factors situated within a contemporary context referred to as cohort effects. Similar to the socioecological
model,7 this framework supposes that outer rings influence the rings within them. Similar to the pathways linking SES and health
model,8 there are bidirectional relationships and interactions among many of the factors. SES indicates socioeconomic status.

fasting glucose (Figure 3). Importantly, in both children and adults, the proportion of the US population
meeting ideal criteria for blood pressure and total
cholesterol has risen over the past decade, while the
prevalence of ideal BMI and glucose levels has declined.17 There is robust evidence that type 2 DM is
increasing in younger individuals worldwide as well.18
Although use of traditional cigarettes has declined for
young adults, they are increasingly using e-cigarette
products that appear to pose cardiovascular risk.19–21
E-cigarette use by young adults is also associated
with subsequent adoption of traditional tobacco
products22 thus, this may portend a worsening of the
smoking metric in future years.

Although not 1 of the original 7 ideal CVH metrics, sleep health is also critical to CVH and is insufficient among young adults, with 38% reporting
an inadequate sleep duration (<7 hours per night).23
Adolescents with inadequate sleep are more likely
to be obese and have elevated glucose and insulin
levels, higher blood pressure, greater fat mass, and
more behavioral risk factors such as physical inactivity and an unhealthy diet.24,25 Adults with inadequate
sleep duration are more likely to be obese and physically inactive, report substance use including use of
tobacco products, experience depressed mood and
anxiety symptoms, and develop chronic diseases
such as hypertension and DM.23,26
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Figure 2. Causes of variation in trajectories of cardiovascular health.
The 3 cases illustrated in the figure vary from having a low early vulnerability burden that allows CVH to develop maximally (green
curve) to having a high vulnerability burden that constrains the development of CVH (red curve). The case illustrated by the green curve
shows high resilience to the young adult period of risk (ie, maintaining the high starting level of CVH until late in life). Both the yellow
and the red curves show loss of CVH during the young adult risk period, illustrating a lack of resilience to the challenges imposed by
this life period. Both the green and the yellow curves illustrate a steep slope, where CVH is lost rapidly. The comparison of the green
and yellow curves illustrates that the clinical impact of such a rapid loss of CVH varies depending upon its timing in the life course.
These 3 simplified curves are shown for illustrative purposes; dynamic changes to CVH trajectories across the life course are likely
caused by alterations in the enduring vulnerabilities and risk behaviors through changes in life circumstances, individual, or public
health interventions. CAC indicates coronary artery calcium; CHF, congestive heart failure; CIMT, carotid intima media thickness; CVA,
cerebral vascular accident; CVD, cardiovascular disease; CVH, cardiovascular health; HTN, hypertension; MI, myocardial infarction;
PVD, peripheral vascular disease; and YA, young adulthood.

MULTILEVEL INFLUENCES ON THE
CVH OF YOUNG ADULTS
As depicted in Figures 1 and 2, many factors influence the CVH trajectory of young adults by contributing to either the slowing or the acceleration of the
development of CVD. A selection of these factors is
presented below, beginning with those unique to individuals, followed by interpersonal and community
factors, and cohort effects. Similar to the socioecological model,7 this framework supposes that outer
levels influence the levels within them. Similar to the
pathways linking SES and health model,8 there are
bidirectional relationships and interactions among
many of the factors.

Genetic Factors
Genetic conditions cause premature heart disease,
including familial hypercholesterolemia (prevalence
1:250). Emerging data suggest the addition of a genetic risk score to conventional risk factors may improve the prediction of accelerated subclinical

atherosclerosis in younger adults and premature onset
of CHD events.27–31 For example, a 182-variant polygenic risk score predicted a 2-fold increase in risk of
premature coronary artery disease (≤40 years old for
men and ≤45 years old for women), a rate similar to
that observed in individuals with heterozygous familial
hypercholesterolemia.28

Gender
The young adult years hold important CVD prevention implications for women. CVD remains the leading cause of mortality among women in the United
States and developed countries.32 Women experience a higher fatality rate following a first myocardial
infarction, and despite an overall decline in the CVD
death rate in the United States, the rate of decline has
been slower for women compared with men. In addition, the death rate is 70% higher in Black women
compared with White women.33 Two-thirds of CHD
sudden deaths occur in women with no previous
symptoms compared with half of CHD sudden deaths
in men. It is now evident that this excess mortality
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Figure 3. Prevalence of adolescents (ages 12–19 years), young adults (ages 20–39 years), and middle-aged adults (ages
40–59 years) meeting ideal status for each of the 7 cardiovascular health metrics.
Prevalence (unadjusted) estimates of US adults across 3 age strata meeting ideal status for each of the 7 metrics of cardiovascular
health as reported in “Heart Disease and Stroke Statistics—2020 Update” from the American Heart Association.17 BMI indicates
body mass index; and CVH, cardiovascular health. *Healthy diet score reflects 2013 to 2014 NHANES (National Health and Nutrition
Examination Survey). Source: National Center for Health Statistics, NHANES, 2015 to 2016 (healthy diet score, 2013 to 2014).
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is based in part on the increased death rate among
premenopausal women, although less is known regarding coronary artery disease among this group.34
Recent data on 20-year trends in acute myocardial
infarction demonstrate that the proportion attributable to patients >55 years old has increased from 27%
to 32%, with the largest increases observed in young
women.2 Additionally, women 18 to 44 years old have
a higher incidence rate of ischemic and nonischemic
stroke compared with men of the same age.35 Thus,
the detection of elevated risk in young women and a
greater understanding of gender-related differences
may provide a critical opportunity to delay or prevent
onset of CVD in women.

Pregnancy
More than 80% of American women bear a child during their young adult years36; pregnancy can be viewed
as a “stress test,” with adverse pregnancy outcomes
associated with increased future CVD. Hypertensive
disorders of pregnancy (eg, preeclampsia, gestational
hypertension) affect up to 7% of births. A firmly established link exists between the development of hypertension during pregnancy and a 2- to 8-fold higher
risk of hypertension, CVD, and renal disease later in
life.37 Rates of chronic hypertension 2 to 5 years after

affected pregnancies are as high as 50% following
early-onset preeclampsia, 39% after gestational hypertension, and 25% following late-onset preeclampsia.38 By comparison, hypertension rates in women
with normotensive, term births are very low (3.8%)
2 to 7 years after delivery.39 Diastolic dysfunction
and asymptomatic heart failure have been detected
4 years postpregnancy in 25% of women with preeclampsia.40 Women with preeclampsia have a higher
risk of CVD within 5 years after delivery, suggesting
that the short- and long-term cardiovascular sequelae
are high.41,42 Thrombotic events are more likely in the
period immediately following pregnancy.43
Gestational DM, which affects up to 10% of pregnancies, is associated with a 50% to 85% higher
CVD risk in women.42,44–46 Nearly half of women who
experience gestational DM will develop type 2 DM
within 10 years after pregnancy.47,48 Gestational DM is
also related to risk of atherosclerosis, even in women
who do not progress to DM.49 Lactation may mitigate some of these adverse maternal consequences
of gestational DM, suggesting that the reproductive
years also present opportunities for risk reduction.50
Other complications such as preterm birth are also
linked to CVD risk.51–54 Further, there is an alarming
increase in severe maternal morbidity and mortality
in the United States, the dominant cause of which
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is cardiovascular in nature.55 There are also profound racial disparities, with Black women carrying
the highest risk for these severe events compared
with White women.56 Evidence-based strategies to
increase CVD risk evaluation during preconception,
prenatal, and postnatal care are needed, as are interventions to mitigate CVD risk during this critical time
for young adult women.

Psychological Factors

Downloaded from http://ahajournals.org by on October 19, 2020

Psychological stressors are associated with CVD risk
behaviors and CVD.57 Acute mental stress is associated
with alterations in myocardial blood flow, and chronic
exposure to stress is associated with alterations in
inflammation signaling pathways.58,59 Young adults
commonly face a variety of psychological stressors,
including neighborhood factors and sequelae of adverse childhood experiences, as well as financial hardships, relationship changes, and discrimination based
on race, gender, sexual orientation, or other societally
disadvantaged situations. The cumulative effects of an
increasing number of stressors, as well as the protective effects of individual and collective resilience factors, are active areas of investigation.
Three-fourths of mental health disorders are present by 24 years old.60 Compelling evidence suggests
that major depression and depressive symptoms predict premature heart disease morbidity and mortality.
Putative mechanisms include standard biological and
lifestyle factors, inflammation, oxidative stress, and
endothelial dysfunction.61 An analysis of data from
the National Survey on Drug Use and Health for the
years 2005 to 2015 found an increasing prevalence
of depression in the United States, with adolescents
and young adults showing the largest increases, to
13% and 10%, respectively.62 A substantial decline in
CVH among young adults may be caused by mental
health disorders and related obesity, physical inactivity,
smoking, and disturbed sleep,61 although this remains
an area for investigation.

Adverse Childhood Experiences
Adverse early life experiences may be particularly damaging to CVH in young adults. Typically, these include
physical and sexual abuse, neglect, a family member
with mental health problems, incarceration of a parent,
and sometimes poverty. In a sample of 29 229 adult
men and women, more than 50% reported at least 1
form of childhood adversity; 17% reported 4 or more
adverse experiences.63 Not only do adverse early life
experiences predict depression, but they are also related to behavioral and physiologic cardiovascular risk
factors.64–67 The accumulation of adverse early life experiences is predictive of clinical CVD in adulthood.68
A meta-analysis of 9 studies (15 effects) that reported

hazard ratios (HRs) and 29 studies that reported odds
ratios (ORs; 62 effects) found significant associations
between cumulative childhood adversity and adult
cardiometabolic disease (HR, 1.42, 95% CI, 1.20–1.67;
OR, 1.36, 95% CI, 1.27–1.46). We know of no evidence
to suggest that the prevalence of adverse child experiences is declining. Interventions to decrease exposure
to childhood adversities and mitigate their downstream
effects are needed.

Social Relationships
In adults, lower social support, less integration into
social networks, and greater social isolation are associated with increased risk of morbidity and mortality.69 Less evidence regarding the cardiovascular risk
of social relationships is available in adolescents and
young adults. The Dunedin Multidisciplinary Health
and Development study showed that social isolation in
childhood (5–11 years old) based on parent and teacher
ratings predicted the age 26 summary index of lipids,
blood pressure, BMI, waist circumference, glycated
hemoglobin, and maximum oxygen consumption.70
These effects were independent of childhood family
SES and overweight. Peer social integration based on
parental reports of time their sons spent with friends
from ages 7 to 16 was related to blood pressure and
BMI when men were in their thirties.71 These relationships were also independent of family SES, childhood
BMI, and social integration in adulthood. Data from the
Add Health (National Longitudinal Study of Adolescent
to Adult Health) study indicated that greater social integration within peer networks, school, family, and community during adolescence was associated with lower
levels of inflammation, blood pressure, BMI, and waist
circumference in young adulthood.72 Several studies
have reported that being a victim of bullying was associated with inflammation, obesity, and psychosocial
risk factors, in addition to its mental health consequences.73,74 The long-term impact of early social relationships and social relationships in young adulthood
are an important area for future research.

Sociodemographic Factors
SES has a profound influence on adult CVD risk,
regardless of whether SES is based on the education, the income, or the occupation of the individual or of family members, or whether these factors
apply to the neighborhood.10 Many explanations
of SES and CVD risk association have focused on
poverty, but it appears that the relationship of SES
and health is monotonic, such that each increasing level of SES is associated with better health.
Studies examining the influence of SES across the
life course have found that low SES in childhood is
related to adult CVD morbidity and mortality, even
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when statistical adjustments are made for adult
SES.75,76 Extensive reviews of the literature show
that lower SES in youth is associated with CVD risk
factors, including greater exposure to passive and
active smoking, physical inactivity (eg, more hours
watching television), obesity, poor sleep health, and
central adiposity.77–79 In the Add Health study, lower
SES during adolescence was related to a higher
Framingham risk score 14 years later.80 Mediation
analyses showed that educational attainment, financial stress, and lack of medical/dental care were
key pathways to high-risk scores. In the same study,
lower family income was related to higher systolic
blood pressure.81
Black and Hispanic youth are more likely to grow
up in lower SES families and live in lower SES neighborhoods than their White and Asian counterparts.
Further, although there is evidence from studies that
Black adults receive less of a health benefit from
higher SES status than White adults,82,83 only a few
studies among youth simultaneously consider SES
and minority status and whether the effects are independent or synergistic.84 In an analysis of National
Health Interview Survey data for US children 0 to 18
years old, lower parental education was associated
with higher rates of “circulatory conditions” in Black
and White children and were null or reversed in Asian
and Hispanic children.85 In the Add Health study, the
influence of SES on obesity differed by race and gender.86 In several studies of healthy children, low SES
was related to higher ambulatory blood pressure
throughout the school day in Black and White children, and family income was related to high nighttime
pressure in Black children only.87,88 Taken together,
the stage is set by adolescence for a long-lasting effect of family SES on CVH into adulthood, with more
adverse among Black and Hispanic young adults,
with some gender-specific differences.

Neighborhood Factors
Findings from the Add Health study also indicate that
the prevalence of obesity, as well as high systolic and
diastolic blood pressures and metabolic syndrome,89
is lower in young adults who never lived in poor neighborhoods, compared with those who later or consistently lived in poor neighborhoods as adolescents.90,91
Independent of neighborhood poverty, aspects of
the neighborhood physical environment, including
access to healthy foods, walkability, and transportation have been consistently linked to behaviors such
as smoking, physical activity, and dietary intake, as
well as a range of CVD risk factors including BMI,
hypertension, and DM.92–97 Aspects of the neighborhood social environment including crime, perceptions of safety, and reports of neighborhood social

cohesion have also been associated with a range of
indices of CVD risk, including smoking, physical inactivity, dietary quality, insomnia, hypertension, and
increased BMI.93,98–101

Cohort Effects
Regardless of treatment modality or preventive strategy, trials of any intervention to improve CVH during
young adulthood will need to understand and navigate the unique socioeconomic characteristics exhibited by 21st century young adults. Young adults
living in the United States today are less likely than
previous generations to marry, have children, and
own their own home.102 The modal living arrangement
is with their parents (33%), and 1 in 4 young adults
who live at home are neither working nor in school.102
Furthermore, though young adults living in the United
States today are more educated than previous generations, they have taken on much more debt related to
their education. Each of these shifts has implications
for the likelihood and ability of young adults to engage
in preventive behaviors and pay for health care. These
contextual factors require consideration for both initiating and sustaining lifestyle modifications,103,104 and,
if indicated, starting and maintaining adherence to
antihypertensive, lipid-lowering, or glucose-regulating
medication.105 These demographic trends are seen
most often in highly industrial or postindustrial societies. In other societies and in more rural communities
in the United States and elsewhere, the phenomenon
known as “emerging adulthood,” a delayed transition
to typical adult roles, is less common.12
Technological advances have changed the nature
of work and leisure time for young adults around the
world, and in both rural and urban settings. Young
adults are the most likely age group to own a smartphone (92% in 2017), use social media (86%), and be
dependent on their smartphone for accessing the internet.106 Thirty-nine percent of young adults report
they are “constantly online” and 49% report they are
online “multiple times per day.”107 The beneficial and
harmful effects of young adults being connected to
these electronic devices for much of their waking, and
even their sleeping hours, are unclear. Electronic media
usage has been associated with insufficient sleep,108
physical inactivity,109 increased caloric intake,110 and
elevated BMI111 in young adults, although some studies find improved nutrition and physical activity among
young adults who use health-related apps.112
Early young adulthood, between 18 and 21 years
old, is when individuals transition from pediatric-oriented to adult-oriented healthcare systems in the
United States.113 Consistent engagement with medical care is essential for young adults with higher CVD
risk. Even among insured young adults, a longer time
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between physician visits is associated with worse hypertension control.114 Yet, many young adults have
a prolonged gap in care when transferring across
healthcare systems. A recent national retrospective study of insured young adults found a gap of
20.5 months for office visits and 41.7 months for preventive visits when transitioning from an adolescent
to adult medical practice.115 Males and young adults
from lower-income neighborhoods experienced even
longer gaps in care.115 Young adults also have relatively low rates of preventive care service utilization as compared with other age groups. The 2014
to 2016 Medical Expenditure Panel Surveys, which
reflect implementation of the Affordable Care Act,
found that only 23% of young adult men and 42% of
young adult women received a routine primary care
examination. Of those who attended any healthcare
visit in a 3-year period, 86% received blood pressure
screening, but only 42% received cholesterol screening. Rates of preventive care were higher in females,
young adults with higher reported income, and those
with health insurance.116

CAUSES OF VARIATION IN
TRAJECTORIES OF CVH
Downloaded from http://ahajournals.org by on October 19, 2020

Optimal preventive interventions should consider not
only who is at greatest risk of adverse CVD outcomes
based on exposures and individual susceptibility, but
also when risk develops and when intervention would
be most beneficial. The schematic in Figure 2 illustrates different trajectories of loss of CVH over the
lifespan in relation to enduring vulnerabilities from the
influences described above, individual risk behaviors,
and traditional risk biomarkers. CVD risk factors vary
in their temporal trajectories across the life course.117,118
The first parameter in the model is maximal capacity
for CVH, represented by the y-axis intercept. Various
genetic, intrauterine, sociodemographic and life event
factors, operating from conception throughout childhood, function as vulnerabilities to impact the maximum
capacity for CVH.119,120 The second parameter reflects
the degree of resilience against loss of CVH present
during young adulthood. The third parameter is the
slope of the trajectory of loss of CVH; steeper slopes
represent more rapid loss. Each curve in Figure 2 illustrates how these parameters may influence the timing
and rate of loss of CVH. Optimal is decline after age
70 to 80 years based on lifelong stably high CVH level
(green curve in Figure 2). This illustrates the advantageous compression of morbidity until achieving old
age based on maximal capacity and healthy lifestyle.121
Most typical is rapid decline from the presence of prior
moderate CVH during young adulthood; this presages
reaching suboptimal CVH during late adulthood (yellow

curve in Figure 2). Unfavorable levels of cardiometabolic and biochemical markers (eg, increased systolic
blood pressure, increased waist circumference, and
decline of glomerular filtration rate) are evident at least
15 to 20 years before CVD diagnosis, indicating that
risk is partly determined by or during young adulthood.122 Those with limited maximal capacity, adverse
circumstances, and severe or multiple risk will experience CVD in young adulthood (red curve in Figure 2).

PATHOPHYSIOLOGIC PROGRESSION
AND RISK PREDICTION: FROM
SUBCLINICAL CARDIOVASCULAR
MARKERS TO CVD
Subclinical Atherosclerosis and CVD Risk
Prediction
Epidemiologic and clinical studies have established
that atherosclerosis can start during the childhood
years and progress through young adulthood, leading
to CHD by middle age.123,124 The PDAY (Pathobiological
Determinants of Atherosclerosis in Youth) study confirmed that advanced atherosclerosis can start in
late adolescence, with progression of atherosclerotic
plaque in relation to CVD risk factors occurring in the
third and fourth decades of life.123 The advanced atherosclerotic lesions seen in some young adults are of
the type that can rupture and produce acute events.125
Preliminary analyses, using CARDIA (Coronary Artery
Risk Development in Young Adults) study data, support a relationship of these high-grade lesions with
atherosclerotic events.126 The major traditional risk factor predictors of advanced atherosclerosis in the PDAY
study were DM, dyslipidemia, smoking (particularly for
atherosclerosis in the abdominal aorta), hypertension,
and obesity (in men). Effects on traditional risk factors, oxidative stress, and endothelial dysfunction have
been described as pathways whereby lifestyle risk factors convert to cardiometabolic risk factors and further the progression to atherosclerosis and CVD.127,128
However, lifestyle risk factors also occur against a
background of variable inherited and acquired individual vulnerability to atherosclerosis and cardiovascular
events28,29 and in a context that offers more or less
socioenvironmental support.129
Current risk prediction equations for atherosclerotic cardiovascular disease (ASCVD; defined as a
nonfatal myocardial infarction [heart attack], CHD
death, or stroke)130,131 use the traditional risk factors of
age, sex, DM, smoking, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), systolic blood pressure, antihypertensive therapy, as well as race/ethnicity. These equations perform well in non-Hispanic
White and Black women and men 40 to 79 years
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old.132 Insufficient data have been available to develop
ASCVD risk prediction equations for adults <40 years
old, or for other racial/ethnic groups.130
A PDAY risk score was developed to predict the
presence of subclinical atherosclerosis in young adults;
this score is based on age, sex, HDL-C and non-HDL-C,
smoking, blood pressure, and glycosylated hemoglobin. The usefulness of this score was confirmed in both
the CARDIA study133 and the Young Finns Study.134 A
critical finding was that the PDAY score calculated in adolescents (Young Finns Study) or at age 18 to 30 years(CARDIA study) was more predictive than risk factors
measured later in adulthood for higher carotid intima
media thickness or presence/intensity of coronary artery calcium measured 15 to 25 years later. Between
40% and 60% of those with a high PDAY score will have
advanced atherosclerosis. These observations suggest
that atherosclerosis present in young adulthood is the
result of chronic risk exposure over a lifetime; early prevention efforts can reduce the atherosclerotic burden
in middle age.135,136 Longitudinal studies with childhood
and adult measures of subclinical atherosclerosis consistently show independent relationships of youth risk
factors to adult outcomes.137

CVD Risk Based on Hypertension and DM
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There is a high prevalence of uncontrolled hypertension
among young adults.105,138–141 Up to 38% of hypertension goes undetected before age 40.142 Hypertension
in young adulthood has been associated with adverse cardiovascular outcomes later in life, with many
of these events occurring before age 50 years.143–145
Multiple studies have demonstrated that Black young
adult men and women have an earlier onset and more
severe hypertension compared with young adult White
men and women.141,146 Analysis of 24-hour ambulatory blood pressure data found a higher mean 24-hour
blood pressure, higher prevalence of nocturnal hypertension, and higher rates of masked hypertension
among young Black men and women compared with
White men and women of similar age.141,147 Historical
cohort studies also have found more severe baseline
hypertension (>160/95 mm Hg) among Black young
adults and its association with higher rates of hypertension-related mortality.141
More concerning is that the severity of hypertension among Black young adults is often underestimated using blood pressure measurements taken in
a clinic.141,147 Analyses of blood pressure trajectories
highlight the emergence of age, gender, and racial/
ethnic hypertension disparities beginning at least as
early as 8 years old.146 Using 2007 to 2012 data from
the National Health and Nutrition Examination Survey,
there were earlier transitions from ideal blood pressure
(<120/80 mm Hg) to prehypertension, and ultimately

sustained hypertension among boys (compared with
girls) and Black compared with White youth.146 With
the updated 2017 American College of Cardiology
and American Heart Association high blood pressure
guidelines defining hypertension as a blood pressure
≥130/80 mm Hg, there is now a greater prevalence of
elevated blood pressure (120–129/<80 mm Hg, previously “prehypertension”) and hypertension among
young adults.148 Disparities in the incidence and severity of hypertension also contribute to similar disparities
noted in the prevalence of heart failure among young
adults.149 In the CARDIA study, 20-year follow-up of
18- to 30-year-olds found higher rates of incident heart
failure among Black males and females compared with
White men and women. Of note, Black young adults in
the United States carry a disproportionate burden of
many psychosocial contributors to poor CVH including
poverty and stress noted above. Thus, the accrual of
CVD risk for Black young adults can be profound.
The prevalence of DM in adolescents and young
adults is increasing.150,151 Both type 1 and type 2 DM
have been related to early vascular dysfunction, and
share risk factors similar to those for CVD including
hypertension, dyslipidemia, microalbuminuria, inflammation, and hyperglycemia.152 However, young-onset
type 2 DM appears to be associated with manifestation of the vascular abnormalities earlier and at lower
glycosylated hemoglobin levels, despite shorter duration of diagnosed DM.153,154

PRIMORDIAL AND PRIMARY
PREVENTIVE INTERVENTIONS IN
YOUNG ADULTS
Two main intervention strategies are available to curb
longitudinal loss of CVH (Figure 4). Primordial prevention intervenes to deter the development of risk factors
by focusing on the outer level of influences (Figure 1).155
Examples targeting the entire population include media
health education campaigns and policy interventions
(eg, Clean Indoor Air Act, sugar-sweetened beverage tax, fruit and vegetable subsidies, and zoning
ordinances to make neighborhoods more walkable).
Primary prevention treats individuals who already have
risk factors to reduce their odds or slow their trajectory of progression toward CVD events. This is typically
focused on the innermost level of individual influences
(Figure 1).

Role of Healthcare Engagement by Young
Adults for CVH Promotion and Disease
Prevention
For primary prevention to reach young adults with
risk, barriers to young adults’ engagement in health
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Figure 4. Risk factor intervention.
Two main intervention approaches to preventing the development of (primordial prevention) or treating already developed cardiovascular
risk factors (primary prevention). Either intervention approach can deploy behavioral-socioenvironmental or pharmacologic treatment
modalities. The intervention targets depicted (in hexagons) are the established cardiovascular risk factors included in the American
Heart Association’s Simple 7 metric, but might also include developing markers: insufficient sleep, stress/depression, or inflammation.
Downloaded from http://ahajournals.org by on October 19, 2020

care must be overcome. Policies are critically
needed to offer young adults continuous, affordable health insurance and consistent care access
without racial and socioeconomic disparities. At a
healthcare systems level, it is important that primary
and specialty care practices recognize the transitions that occur throughout young adulthood. To
maintain young adults’ continued engagement, traditional outpatient clinics may need to accommodate their preferences for convenient, integrated,
and flexible care, by offering services during evening
or weekend hours or via telemedicine.156 Similarly,
young adults may prefer using technology to schedule health appointments, access health records,
and monitor engagement in health-related behaviors by using their own mobile/wearable devices. By
incorporating data from mobile devices and wearable devices, the healthcare provider can potentially
partner with patients to provide tailored assessments and behavior-change advice.157,158 Although
integration of patients’ digital data into the electronic health record to support connected care remains in its infancy, such infrastructure has already
become a reality at some institutions.159 Expansion
of training programs with a young adult focus, such
as joint pediatric and adult medicine training, can increase developmentally tailored programs for young
adults.160

Community-Based CVH Promotion and
Disease Prevention
Given low overall rates of engagement with traditional
medical settings, novel programs may be needed
to promote healthy behaviors among young adults.
Because young adults are highly represented in the
workforce, health promotion programs delivered in
occupational settings may be particularly beneficial
to promote heart-healthy behaviors.161 Also, linking preventive health care to concern for the environment (eg, lower environmental impact of wholly
plant-based or reduced animal protein diets, walking, or biking) and to other motivational factors may
appeal to young adult values. Similarly, social media
may be harnessed to promote health knowledge and
motivation among difficult-to-reach or disengaged
young adults.162 It is important to respect young
adults’ need for privacy on social media and provide
resources for how to find and identify credible health
information.163 Provision of high-quality, coordinated
care for young adults will require improved communication across healthcare systems and providers
who may work in student health, retail-based, and
urgent-care clinics. By incorporating these care delivery entities outside of traditional health settings,
coordinated care may be able to catch young adults
where they are receiving care.
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Population-Wide Health Interventions
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Population-wide interventions have the potential to
reach those of low SES, smokers, and consumers of
low-cost, unhealthy diets who are often not linked to
medical care. Population-based interventions may be
especially relevant to young adults, who may be disengaged from the formal healthcare sector and may
choose to prioritize immediate concerns over longterm health risks. Some of the best-supported population-wide interventions involve laws and policies.
Two particularly impactful tobacco control policies
legislated at the state or municipal level have been
tobacco product taxation, passed on to the consumers at the point of purchase, and tobacco bans,
which outlaw smoking in workplaces, public transit, restaurants, and bars. The National Longitudinal
Survey of Youth found that a $1 increase in tobacco excise taxes lowers the odds of daily heavy
smoking in young adults (1 or more packs per day)
by 17.9%.164 Young adults living in cities with comprehensive smoking bans were 21.1% less likely to
smoke. Electronic cigarettes share the same addictive properties as traditional tobacco products, but
have only recently become popular among adolescents and young adults. The health effects of electronic cigarettes have not been well-described, but
early evidence shows that young adults who start
as never-smokers and start using electronic cigarettes are 3.6 times more likely to become regular
tobacco smokers than those who avoid electronic
cigarettes.165 This suggests that stronger electronic
cigarette regulation in young adults could limit the
population of young adult and longer-term tobacco
smokers.
Recently, population-wide interventions have
been applied to the risk factors of poor-quality diet
and physical inactivity with the rationale that powerful environmental contexts make individual behavior
changes difficult to sustain. Examples include food
sources dominated by packaged, processed, and
high-calorie foods with low nutritional value and built
and workplace environments that encourage sedentary habits. New York City 2006 government regulation of trans-fatty acid use in restaurant cooking
led to a 62% reduction in mean serum trans fatty
acid levels in adults between 2004 and 2014.166 In
the United Kingdom, food companies were encouraged by the government to make voluntary agreements to lower sodium content in packaged foods
starting in 2006. Young adults in the United Kingdom
(16–34 years old) had the highest sodium consumption at baseline of any age group (6.6 g/d in 2003)
and experienced a 9.5% decrease in daily sodium
intake by 2007.167 An excise tax on sugar-sweetened
beverages introduced in Berkeley, California, led to

reduced consumption of sugar-sweetened beverages
and increased consumption of untaxed beverages
(eg, water).168,169 Not all public health interventions
need be punitive. For example, the US Supplemental
Nutrition Assistance Program, introducing incentive
subsidies to encourage consumption of fruits and
vegetables combined with a sugar-sweetened beverage ban, could lead to substantial lifetime health
gains and be cost-effective.170

Individual Behavioral Interventions
Systematic evidence reviews of behavioral interventions for the general adult population suggest their benefit on intermediate CVD risk factors, diet, and exercise
behaviors,171 as well as tobacco cessation.172 Less evidence exists for young adults specifically. Traditionally,
young adults have been underrepresented in behavioral intervention trials. For example, in a pooled analysis
of lifestyle interventions for weight loss, young adults
represented <10% of the sample, attended 25% fewer
sessions than older adults, and were less likely to be
retained at follow-up.173,174
The EARLY (Early Adult Reduction of Weight through
Lifestyle Intervention) trial, a consortium of 7 randomized controlled trials funded by the National Institutes of
Health, sought to address this gap by enrolling only individuals 18 to 35 years old in 2-year behavioral weight
control interventions.175 The EARLY trial enrolled over
4000 young adults, and had an average retention of
83% at 2 years across all 7 studies, demonstrating that
young adults are interested in and can be successfully
retained in long-term behavioral trials designed specifically for them.175–181 Retention was variable across
populations and follow-up methods; whereas 97% of
weights were obtained using electronic medical records, fewer (68%) were obtained when directly measured in the clinic. Results across EARLY studies were
variable, with some studies showing significant weight
loss178 or weight gain prevention at 2 years181 and others showing only short-term weight loss or effects on
secondary outcomes.175,177,180
In an effort to appeal to young adults, each of the
EARLY studies used digital tools, either alone or in
combination with face-to-face methods. Systematic
reviews and meta-analyses provide evidence that
using digital health tools can produce positive shortterm effects on smoking cessation182 and weight
control.183 Digital and hybrid treatments that combine digital with phone or face-to-face care can vary
significantly with respect to content and intensity.184
Generally, interventions with greater dose, tailoring,
and inclusion of a human coach or counselor have
been more effective. The outcomes across the 7
EARLY trials in young adults are consistent with this
interpretation.
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Moving forward, behavioral research should focus
on optimizing interventions such that more potent, efficient, and scalable interventions are developed and
tested. The multiphase optimization strategy, an engineering-inspired framework, encourages experimental
approaches to the selection and configuration of intervention components. The multiphase optimization
strategy offers a suite of research designs that test how
to optimize interventions so that they achieve the maximum effect possible given resource constraints.185,186
Adaptive interventions (those that deliver sequential
treatments or intensities based on progress) address
heterogeneity of outcomes in behavioral interventions
and may be particularly important for young adults
who face different life events and circumstances that
pose challenges for behavior change.185,187 Just-intime-adaptive interventions capitalize on real-time data
from young adults’ ubiquitous mobile technologies to
adapt the timing and content of interventions day to
day and even moment to moment.188 Emerging genomic, metabolomic, and microbiome data may also
help to understand the heterogeneity of behavioral
treatment outcomes and expand the set of predictors
and treatment-matching variables available to personalize intervention selection.

Individual Pharmacologic Interventions
Downloaded from http://ahajournals.org by on October 19, 2020

Current clinical practice guidelines for the primary prevention of ASCVD have been based on evidence from
cardiovascular outcomes trials that have enrolled individuals ≥40 years old for the end points of ASCVD
events, heart failure, cardiovascular or total mortality, or
atherosclerosis progression.131,189 Few trials targeting
the exclusively primary prevention population included
participants who were <50 years old: Ages ranged
from a mean of 57 to 66 years old.190–193 An ongoing
10-year primary prevention statin trial is enrolling men
35 to 50 years old and women 45 to 59 years old.194
Although randomized trial data suggest that greater reductions in the relative risk of ASCVD occurred when
statins were used in lower-risk (eg, younger) individuals,195 the absolute risk of ASCVD events is low before age 50 years, especially in women, who have a
lower absolute risk of premature CHD.196,197 Clinical
trials with cardiovascular outcomes as end points in
younger adults would require either a very large sample size and duration >5 years, identification of very
effective interventions with large reductions in relative
risk of ASCVD, or more precise identification of the
most susceptible populations with the highest risk of
nearer-term ASCVD events.
On the other hand, trials focused on preventing
the development or progression of atherosclerosis,
early predictors of heart failure, or progression of hypertension are feasible in younger adults. Populations

at higher risk in young adulthood include those with
hypertension, early-onset DM (type 1 or type 2), familial hypercholesterolemia, or multiple risk factors
associated with obesity. It could be expected that
prevention of atherosclerosis or stabilization of early
atherosclerotic plaque would largely prevent the subsequent manifestation of clinical ASCVD later in life.
Because apolipoprotein-B containing lipoproteins
appear to play a key causal role in the development
and progression of atherosclerosis, interventions to
lower LDL-C or non-HDL-C may hold promise for
influencing atherosclerosis progression.198 Clinical
trials of high-intensity statins and proprotein convertase subtilisin-like/kexin type 9 monoclonal antibodies have shown that atherosclerotic plaque volume
can be reduced in middle-aged adults with more advanced stages of atherosclerosis.199 However, animal
data suggest that intensive LDL-C lowering in younger
high-risk adults may have an even greater impact
on plaque regression and the potential to normalize
arterial function.198,200 Validation of this approach in
cardiovascular outcomes trials would also lay the
groundwork for an early-intervention approach to
lifetime ASCVD prevention. Notably, proprotein convertase subtilisin-like/kexin type 9 inhibition provides
a promising target for such interventions because it
is the key regulator of LDL-C receptor expression,
though available drugs are costly.201
Some evidence suggests regression of early atherosclerosis, reduction in arterial stiffness, and normalization of endothelial function could also prevent or
delay the later development of hypertension.202–205 The
urgency to reduce premature heart failure, stroke, and
chronic kidney disease among young adults is increasingly recognized; multiple young adult hypertension
trials are in progress.206–208 Several statin trials have
found reductions in blood pressure and hypertension
incidence in statin-treated patients.209 Proprotein convertase subtilisin-like/kexin type 9 inhibitors have also
recently been shown to improve endothelial function
in proportion to the magnitude of LDL-C lowering.210
Similar approaches have been taken to prevent progression of hypertension or improve subclinical markers of future heart failure.211 The new blood pressure
guidelines present new opportunities to discuss and
launch trials to improve blood pressure management
in young adults, including studies of interventions to
improve treatment adherence that have the potential to prevent millions of CVD events.212 In individuals
with DM, ongoing trials seem reassuring with respect
to cardiovascular safety of newer agents such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. These agents
may prove to be significant adjunct therapies in the
prevention of CVD in young adults with obesity and
DM.
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Imaging data, coupled with risk factor, genetic, and
metabolomics characteristics, could potentially be used
to characterize the phenotypes of the young adults
most responsive to intensive LDL-C-lowering therapies,
antihypertensive therapy, or for planning future definitive
trials with cardiovascular outcomes,198 particularly if the
markers have strong associations with future events.
Imaging data are available to understand the factors
influencing progression of atherosclerosis throughout
the lifespan. No data are available regarding the impact
of earlier treatment of atherosclerosis. Intimal medial
thickness has been assessed in European ancestry
children and younger adults, with limited long-term follow-up or treatment response data. Coronary artery
calcification measured by computed tomography is
associated with the presence of advanced plaque and
increased risk of cardiovascular events, but cannot be
used to assess response to therapy.213–215 Moreover,
coronary artery calcium occurs later in the course of
atherosclerosis progression and may be absent in highrisk younger adults with a substantial burden of noncalcified plaque.197 Computed angiographic tomography
has emerged as the preferred choice for evaluating and
characterizing composition of coronary plaque, and
strongly predicts ASCVD events and response to therapy.216–223 The latest generation of scanners has less
radiation exposure than a mammogram. Newer noninvasive technologies such as positron emission tomography can assess inflammation and are promising for
understanding earlier stages of plaque development.197
A similar process could be followed to examine cardiac
function markers, as assessed by echocardiography
and magnetic resonance imaging, in relation to future
heart failure risk.224,225

RESEARCH OPPORTUNITIES
Given the demonstrated necessity of improving the
CVH of young adults, prioritizing research areas will
be critical. Future research should focus on identifying effective strategies that improve control of risk
biomarkers via evidence-based strategies and promote healthy lifestyle behaviors. Emphasis should be
placed on young adults who experience health disparities and are at highest risk for early cardiovascular
events, as they often experience inadequate education, lower SES, exposure to psychosocial stress, and
identification as part of a racial/ethnic minority population.226 Given the unique characteristics of today’s
contemporary young adults, future research should
integrate cutting-edge digital approaches into all aspects of study design. This could include leveraging
innovative assessment methods that easily integrate
patient self-entry of data, transmit home blood pressure measurements, and automatically capture dense

digital data from wearable devices (eg, physical activity sensors, sleep trackers, continuous glucose monitors). The use of population management tools to
capitalize on the wealth of information available from
electronic health records has the potential to improve
reach and recruitment of high-risk young adults. Next
steps in leveraging technology include exploring how
digital tools can extend traditional retention strategies (eg, use of reminders, financial incentives) and
can inform emerging strategies that build participant
trust.227–229
Here, we prioritize 3 critical research areas: primordial prevention, primary prevention, and implementation
science. First, research on primordial prevention—the
improvement in population-based metrics such as tobacco use, obesity prevalence, dietary choices, physical activity, and sleep habits—could identify new ways
to lower the prevalence of cardiovascular risk factors
in the population. Tobacco control provides many examples of strategies to lower population risk exposure,
as does the decades-long success in lowering cholesterol levels in the population via awareness of excess
saturated fat intake and elimination of trans fats from
the food chain. Public health intervention strategies to
curb the obesity epidemic and improve engagement of
young adults with preventive health care are promising
opportunities.
Second, clinical trials of promising primary prevention strategies could identify new approaches to
prevention of CVD in young adults, especially those
with significant behavioral risk factors, genetic factors, and presence of subclinical cardiovascular
dysfunction or vascular abnormalities. For example,
these trials could target women with high-risk pregnancies or individuals with multiple risk behaviors or
psychosocial stressors, such as exposure to childhood adversity. Potential outcomes include improvements in end-organ injury (eg, slowed atherosclerosis
progression, improved vascular function, improved
cardiac function, prevention of incident hypertension,
prevention of renal injury) as well as reduction of early
ASCVD events.
Third, implementation science studies could inform
approaches to increase the uptake of effective primary
prevention and risk factor control strategies for young
adults with established risks (hypertension, dyslipidemia, DM) for whom evidence-based treatment guidelines exist. Gaps exist in recognition of risk, initiation
of treatment, and adherence to treatment, some of
which may be created by disparities based on race,
ethnicity, gender, education, and lack of health insurance coverage. In young adults, an important question
is whether it may be more useful to set implementation
trials in community settings (eg, workplaces, pharmacies, beauty and barbershops, churches) rather than
in medical clinics.
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SUMMARY
This review summarizes discussions from a 2-day
workshop in Bethesda, Maryland, in September 2017
to identify research challenges and opportunities related to the CVH of young adults (18–39 years old).
There are substantial observational data documenting
lack of progress in CVD prevention in this group, as
evidenced by the significant prevalence of risk factors
attributable to multiple contributors. Significant knowledge gaps remain concerning the ability of public
health agencies and/or healthcare delivery systems to
act on this information. Future research opportunities
include understanding the influence of the substantial
change in the lifestyles of young adults over the past
few decades, addressing the lack of engagement of
young adults in the healthcare system, developing interventions to mitigate health disparities, and addressing the paucity of clinical trials for both behavioral and
pharmacologic interventions. Given strong evidence
that the origins of chronic CVD begin at a young age,
the greatest opportunity to eradicate heart disease in
the future is likely primordial and primary prevention
beginning in young adulthood, if not earlier.
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